Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): A retrospective study from the European Cooperative Group for Blood and Marrow Transplantation

Journal of Clinical Oncology

Volumn 26, Issue 19, 2008, Pages 3183-3188

  Gorin, Norbert Claude ^a   Labopin, Myriam ^b   Frassoni, Francesco ^b   Milpied, Noel ^b   Attal, Michel ^b   Blaise, Didier ^b   Meloni, Giovanna ^b   Iori, Anna P ^b   Michallet, Mauricette ^b   Willemze, Roel ^b   Deconninck, Eric ^b   Harousseau, Jean Luc ^b   Polge, Emmanuelle ^b   Rocha, Vanderson ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOME ABERRATION; CONTROLLED STUDY; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; ADOLESCENT; AGED; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; CHI SQUARE DISTRIBUTION; CHROMOSOME 16; CHROMOSOME 21; CHROMOSOME 8; CHROMOSOME INVERSION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METHODOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; QUESTIONNAIRE; RECURRENT DISEASE; REMISSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CHI-SQUARE DISTRIBUTION; CHROMOSOMES, HUMAN, PAIR 16; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INVERSION, CHROMOSOME; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; QUESTIONNAIRES; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 49249096735     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.3106     Document Type: Article

References (25)

1. Bloomfield CD, Lawrence D, Byrd JC, et al: Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173-4179, 1998
2. Byrd JC, Mrozek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325-4336, 2002
3. Marlton P, Keating M, Kantarjian H, et al: Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. Leukemia 9:965-971, 1995
4. Stone RM, O'Donnell MR, Sekeres MA: Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 98-117, 2004
5. Cassileth PA, Harrington DP, Appelbaum FR, et al: Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 339:1649-1656, 1998
6. Grimwade D, Walker H, Oliver F, et al: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial: The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92:2322-2333, 1998
7. Slovak ML, Kopecky KJ, Cassileth PA, et al: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96:4075-4083, 2000
8. Burnett AK, Wheatley K, Goldstone AH, et al: The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: Results of the UK MRC AML 10 trial. Br J Haematol 118:385-400, 2002
9. Heil G, Krauter J, Raghavachar A, et al: Risk-adapted induction and consolidation therapy in adults with de novo AML aged ≤ 60 years: Results of a prospective multicenter trial. Ann Hematol 83:336-344, 2004
10. Yang DH, Lee JJ, Mun YC, et al: Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation. Am J Hematol 82:1-5, 2007
11. Delaunay J, Vey N, Leblanc T, et al: Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): A survey of 110 cases from the French AML Intergroup. Blood 102:462-469, 2003
12. Nguyen S, Leblanc T, Fenaux P, et al: A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): A survey of 161 cases from the French AML Intergroup. Blood 99:3517-3523, 2002
13. Gooley TA, Leisenring W, Crowley J, et al: Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 18:695-706, 1999
14. Fine JP, Gray RJ: A proportional hazards model for subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
15. Friedman AD: Runx1, c-Myb, and C/EBPalpha couple differentiation to proliferation or growth arrest during hematopoiesis. J Cell Biochem 86:624-629, 2002
16. Licht JD, Sternberg DW: The molecular pathology of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 137-142, 2005
17. Pabst T, Mueller BU, Harakawa N, et al: AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med 7:444-451, 2001
18. Kundu M, Liu PP: Function of the inv(16) fusion gene CBFB-MYH11. Curr Opin Hematol 8:201-205, 2001
19. Morschhauser F, Cayuela JM, Martini S, et al: Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: A multicenter study of 51 patients. J Clin Oncol 18:788-794, 2000
20. Marcucci G, Caligiuri MA, Bloomfield CD: Molecular and clinical advances in core binding factor primary acute myeloid leukemia: A paradigm for translational research in malignant hematology. Cancer Invest 18:768-780, 2000
21. Suciu S, Mandelli F, De Witte T, et al: Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): An intention-to-treat analysis of the EORTC/ GIMEMAAML-10 trial. Blood 102:1232-1240, 2003
22. Cahn JY, Labopin M, Sierra J, et al: No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission: Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 110:308-314, 2000
23. Kuwatsuka Y, Miyamura K, Suzuki R, et al: Haematopoietic stem cell transplantation for acute myeloid leukaemia with t(8;21): Results of 274 transplanted patients from Japanese Registry. Bone Marrow Transplant 39, 2007 (abstr O140)
24. Stentoft J, Hokland P, Ostergaard M, et al: Minimal residual core binding factor AMLs by real time quantitative PCR: Initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse. Leuk Res 30:389-395, 2006
25. Krauter J, Gorlich K, Ottmann O, et al: Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. J Clin Oncol 21:4413-4422, 2003